RespireRx Pharmaceuticals Inc. Overview
Pro stress-test →RespireRx Pharmaceuticals is engaged in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The company had its registration revoked by the SEC effective November 14, 2025, transitioning from public trading while retaining its corporate structure and pipeline assets.
Strategic Profile
Pro stress-test →The company has moved its core drug platforms into separate subsidiaries: ResolutionRx Ltd (cannabinoids) and EndeavourRx LLC (neuromodulators). The company's lead GABAkine, KRM-II-81, is in preclinical development for the treatment of epilepsy, with funding from the National Institutes of Health. RespireRx has stated it plans to file a Form 10 to return to public status, with indication it would wait until after December 31, 2025, to file this form.
Competitive Landscape
Pro stress-test →RespireRx competes in early-stage neurological and psychiatric drug development against larger pharma companies (Eli Lilly, Johnson & Johnson) and specialized biotech firms (Neurochem, Biohaven) focused on epilepsy, ADHD, and sleep disorders. The company's proprietary GABAkine and ampakine platforms offer differentiated mechanisms, but the company's diminished scale and delisted status create competitive disadvantages in partnerships and financing.
Industry Context
RespireRx Pharmaceuticals Inc. operates in Neurological drug development.
Key facts
Founded: 1987 · Headquarters: Glen Rock, NJ, USA · Employees: 6 · Revenue: N/A · Market cap: $658K–$849K (as of March 2026)